374 related articles for article (PubMed ID: 23758736)
1. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.
Gupta PK; Chullikana A; Parakh R; Desai S; Das A; Gottipamula S; Krishnamurthy S; Anthony N; Pherwani A; Majumdar AS
J Transl Med; 2013 Jun; 11():143. PubMed ID: 23758736
[TBL] [Abstract][Full Text] [Related]
2. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Autologous Cell-based Therapy in Patients with No-option Critical Limb Ischaemia: A Meta-Analysis.
Wahid FSA; Ismail NA; Wan Jamaludin WF; Muhamad NA; Mohamad Idris MA; Lai NM
Curr Stem Cell Res Ther; 2018; 13(4):265-283. PubMed ID: 29532760
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
[TBL] [Abstract][Full Text] [Related]
5. A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.
Arango-Rodríguez ML; Mateus LC; Sossa CL; Becerra-Bayona SM; Solarte-David VA; Ochoa Vera ME; Viviescas LTG; Berrio AMV; Serrano SE; Vargas O; Isla AC; Benitez A; Rangel G
Stem Cell Res Ther; 2023 Aug; 14(1):221. PubMed ID: 37626416
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
[TBL] [Abstract][Full Text] [Related]
7. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.
Gupta PK; Krishna M; Chullikana A; Desai S; Murugesan R; Dutta S; Sarkar U; Raju R; Dhar A; Parakh R; Jeyaseelan L; Viswanathan P; Vellotare PK; Seetharam RN; Thej C; Rengasamy M; Balasubramanian S; Majumdar AS
Stem Cells Transl Med; 2017 Mar; 6(3):689-699. PubMed ID: 28297569
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective.
Gremmels H; Fledderus JO; Teraa M; Verhaar MC
Stem Cell Res Ther; 2013; 4(6):140. PubMed ID: 24246031
[TBL] [Abstract][Full Text] [Related]
9. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A
JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
Powell RJ; Goodney P; Mendelsohn FO; Moen EK; Annex BH;
J Vasc Surg; 2010 Dec; 52(6):1525-30. PubMed ID: 21146749
[TBL] [Abstract][Full Text] [Related]
11. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
[TBL] [Abstract][Full Text] [Related]
12. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
[TBL] [Abstract][Full Text] [Related]
13. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).
Shirbaghaee Z; Heidari Keshel S; Rasouli M; Valizadeh M; Hashemi Nazari SS; Hassani M; Soleimani M
Stem Cell Res Ther; 2023 Jul; 14(1):174. PubMed ID: 37408043
[TBL] [Abstract][Full Text] [Related]
14. Label extension, single-arm, phase III study shows efficacy and safety of stempeucel® in patients with critical limb ischemia due to atherosclerotic peripheral arterial disease.
Gupta PK; Shivashankar P; Rajkumar M; Mahapatra SS; Desai SC; Dhar A; Krishna V; Raviraja NS; Bhat S; Viswanathan P; Kannan S; Abraham J; Boggarapu H; Manjuprasad MS; Udaykumar K
Stem Cell Res Ther; 2023 Apr; 14(1):60. PubMed ID: 37005673
[TBL] [Abstract][Full Text] [Related]
15. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
[TBL] [Abstract][Full Text] [Related]
16. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial.
Teraa M; Sprengers RW; Schutgens RE; Slaper-Cortenbach IC; van der Graaf Y; Algra A; van der Tweel I; Doevendans PA; Mali WP; Moll FL; Verhaar MC
Circulation; 2015 Mar; 131(10):851-60. PubMed ID: 25567765
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia.
Ishikane S; Ohnishi S; Yamahara K; Sada M; Harada K; Mishima K; Iwasaki K; Fujiwara M; Kitamura S; Nagaya N; Ikeda T
Stem Cells; 2008 Oct; 26(10):2625-33. PubMed ID: 18669910
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study.
Das AK; Bin Abdullah BJ; Dhillon SS; Vijanari A; Anoop CH; Gupta PK
World J Surg; 2013 Apr; 37(4):915-22. PubMed ID: 23307180
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials.
Teraa M; Sprengers RW; van der Graaf Y; Peters CE; Moll FL; Verhaar MC
Ann Surg; 2013 Dec; 258(6):922-9. PubMed ID: 23426345
[TBL] [Abstract][Full Text] [Related]
20. Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial.
Shadmanfar S; Labibzadeh N; Emadedin M; Jaroughi N; Azimian V; Mardpour S; Kakroodi FA; Bolurieh T; Hosseini SE; Chehrazi M; Niknejadi M; Baharvand H; Gharibdoost F; Aghdami N
Cytotherapy; 2018 Apr; 20(4):499-506. PubMed ID: 29428486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
